Obesity is a chronic disease with a continuously rising prevalence that currently affects more
than half a billion people worldwide. Energy balance and appetite are highly regulated via …

Introduction: Postprandial hyperglycemia (PPHG) contributes to micro-and macro-vascular
complications more than fasting hyperglycemia in patients with type 2 diabetes mellitus. Due …

The efficacy of metformin for the treatment of obesity has been evaluated in few clinical trials
with inconclusive results. Moreover, the effectiveness in a real-life outpatient setting has not …

Background For patients with type 2 diabetes who do not achieve target glycaemic control
with conventional insulin treatment, advancing to a basal–bolus insulin regimen is often …

The increasing prevalence of obesity is contributing substantially to the ongoing epidemic of
type 2 diabetes. Abdominal adiposity, a feature of ectopic fat syndrome, is associated with …

The introduction of dipeptidyl peptidase 4 (DPP4) inhibitors for the treatment of Type 2
diabetes acknowledges the fundamental importance of incretin hormones in the regulation …

Anionic exchange resins are bona fide cholesterol-lowering agents with glycemia lowering
actions in diabetic patients. Potentiation of intestinal GLP-1 secretion has been proposed to …

Objective: To examine the efficacy and safety of canagliflozin monotherapy, a
sodium/glucose co-transporter 2 inhibitor, in Japanese type 2 diabetes patients. Methods: In …

Glucagon-like peptide-1 (GLP-1) enhances meal-related insulin secretion, which lowers
blood glucose excursions. In addition to its incretin action, GLP-1 acts on the GLP-1 receptor …

Previous work from our lab has demonstrated that experience with high-intensity sweeteners
in rats leads to increased food intake, body weight gain and adiposity, along with diminished …